Product Information
- 2-[2-[(2E,3aS,4S,5R,6aS)-Hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]acetic ac idZK 96480
- 2-[2-[(2E,3aS,4S,5R,6aS)-Hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiyn-1-yl]-2(1H)-pentalenylidene]ethoxy]acetic acid
- Acetic acid, [(2E)-2-[(3aS,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]-2(1H)-pentalenylidene]ethoxy]-
- Acetic acid,[2-[hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1,6-nonadiynyl)-2(1H)-pentalenylidene]ethoxy]-,[3aS-[2E,3aa,4a(3R*,4R*),5b,6aa]]-
- Aceticacid, [(2E)-2-[(3aS,4S,5R,6aS)-hexahydro-5-hydroxy-4-[(3S,4S)-3-hydroxy-4-methyl-1,6-nonadiynyl]-2(1H)-pentalenylidene]ethoxy]-(9CI)
- Zk 96480
Cicaprost is a guanine nucleotide-binding protein that is used to treat pulmonary hypertension. It has been shown to be effective in experimental models of pulmonary hypertension and has been found to be safe in toxicity studies. Cicaprost inhibits the angiogenic process by inhibiting the production of pro-inflammatory cytokines such as IL-10 and TNF-α. Cicaprost also inhibits cyclase activity, which prevents the formation of prostaglandins and hence lowers inflammation. Cicaprost is an active analogue of prostaglandin E1 (PGE1) with a long half-life, making it suitable for long-term treatment.